Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02339324
Title Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Pittsburgh
Indications

melanoma

Therapies

Interferon alpha-2b

Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.